Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DaveAu who wrote (5889)	11/27/2000 11:07:43 AM
From: Ron Nairn	of 14101

It been stated in prior posts that Rebecca had the UK in her pocket when she set the November 30 forecast and that she was holding out for better labeling authorization. A review of the press release does not clearly state she has it but alludes to Pensaid's superiority... Although there are a number of topical NSAIDs approved in the UK, they are generally not well regarded as they lack strong efficacy data. In contrast, PENNSAID(R) has demonstrated efficacy using the same international standards used to establish the efficacy of oral NSAIDs, including the new COX- 2 selective NSAIDs. Mrs. Keeler noted that "the UK decision validates the safety and efficacy of PENNSAID and we expect its first commercial launch to be an important source of revenue for Dimethaid in 2001 and beyond." Do we assume yes/no? Rondo

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next